EU210 / Eutilex - LARVOL DELTA

Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer. (ASCO 2023) - " Expanding our previous findings with the therapeutic potential of EU103 in a non-small cell lung carcinoma (NSCLC), here, we also proved its therapeutic effect in human ovarian cancer. Almost 300,000 women are diagnosed with ovarian cancer worldwide each year, and ovarian cancer ranks fifth in cancer deaths among women. In the United States alone, we expect approximately 20,000 new diagnoses and more than 12,000 deaths for this year. Given our findings in this study and clinical significance, we propose here the therapeutic potential of EU103, previously developed by our proprietary antibody discovery and engineering technology, in ovarian cancer."

IO biomarker • Preclinical • Brain Cancer • CNS Tumor • Gastric Cancer • Gastrointestinal Cancer • Glioma • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD34 • CD8 • CTLA4 • PD-L1

Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed (clinicaltrials.gov) - P1/2; N=72; Recruiting; Sponsor: Eutilex; N=28 ➔ 72

Clinical • Enrollment change • Epstein-Barr Virus Infections • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα CD8 T cells. (PubMed, Nat Commun) - "Mechanistically, the anti-tumor effect of IL-18Rα subset is mediated by IL-18 signaling and TCR-MHC I interaction. This study highlights the clinical relevance of CD4 in ACT and provides insights regarding the immunological nature of anti-CD4 treatment, which enhances anti-tumor response of CD8 T cells."

Journal • Immunology • Melanoma • Oncology • Solid Tumor • CD8 • IL18

[VIRTUAL] Development of SARS-CoV-2 neutralizing protein by ACE2 receptor engineering for severe infection and patients with underlying diseases. (AACR 2021) - "We generated EU129 with the improved binding affinity and neutralizing activity through ACE2 receptor engineering. It has angiotensin II-converting enzymatic activity for organ protection, thus EU129 is a better therapeutic candidate for severe cases of SARS-CoV-2 infection and patients with underlying diseases such as cancers."

Clinical • Late-breaking abstract • Oncology

Eutilex (263050) R&D momentum to grow stronger, corporate value rise (Maekyung Media Group) - "T-cell therapy AppB&T is in phase 1/2 clinical trial for patients with NK/T lymphoma...Patient administration is expected to begin in early 21st, and data is expected to be released in the second half...Researchers' clinical results will be presented at AACR (American Cancer Society) in April 21. WiT&T...is undergoing phase 1 clinical trials for patients with malignant brain tumors. The results are expected to be announced at the ASCO (American Society of Clinical Oncology) held in June 21. In addition, TAST, a next-generation T-cell therapy technology, is scheduled to apply for a phase 1 clinical trial IND in the second half of 21..."

Enrollment status • IND • New P1 trial • P1 data • P1/2 data • Brain Cancer • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma